Boehringer Ingelheim's new 120 million euro Investment in Greece
- Written by E.Tsiliopoulos
The research-driven biopharmaceutical company Boehringer Ingelheim announced that it will invest 120 million euros to expand and upgrade its plant in Greece.
In a press release on Thursday, the company explained that the Greece-based investment is slotted for its existing plant in Koropi, which is located in the Attica region.
The funds will enable the plant to increase the manufacturing capacity of the plant in regards to new and existing medications and will add 110 new jobs.
Some of the key disease areas addressed by the medications produced by the plant include cardio-renal-metabolic (CRM) diseases, mental health and pulmonary fibrosis.
Exports of a well-known drug for type 2 diabetes, heart failure and chronic kidney disease called Jardiance will be enhanced and sent to the USA.
The ceremony where the announcement was made was attended by Greek Prime Minister Kyriakos Mitsotakis, Greek Minster of State, the Minister of Health and the Minister of Development.
Related items
-
Searching for Answers: What Greeks Googled in 2025
-
Festive Carols and Holiday Cheer at Greece’s Political Hubs
-
Ecumenical Patriarch Bartholomew: Faith should heal wounds and not reignite conflicts
-
Provocative statement from the Turkish Ministry of Defense: The Greek approach is responsible for the violations in the Aegean!
-
Onassis Foundation: Announcement of Scholarships for 2026-27
Latest from E.Tsiliopoulos
- Searching for Answers: What Greeks Googled in 2025
- Festive Carols and Holiday Cheer at Greece’s Political Hubs
- Ecumenical Patriarch Bartholomew: Faith should heal wounds and not reignite conflicts
- Provocative statement from the Turkish Ministry of Defense: The Greek approach is responsible for the violations in the Aegean!
- Onassis Foundation: Announcement of Scholarships for 2026-27
